Abstract
Chronic thromboembolic pulmonary hypertension (CTEPH) is characterized by unresolved thrombi in the pulmonary arteries and microvasculopathy in nonoccluded areas. If left untreated, progressive pulmonary hypertension will induce right heart failure and, finally, death. Currently, pulmonary endarterectomy (PEA) remains the only method that has the potential to cure CTEPH. Unfortunately, up to 40% of patients are ineligible for this procedure for various reasons. In recent years, refined balloon pulmonary angioplasty (BPA) has become an alternative option for inoperable CTEPH patients, and it may be another curative treatment in the future, particularly in combination with prior PEA. Nevertheless, 23% of patients still suffer from persistent PH after BPA. Given that CTEPH shares many similarities with idiopathic pulmonary arterial hypertension (PAH), targeted drugs developed for PAH are also attractive options for CTEPH, especially for inoperable or persistent/recurrent CTEPH patients. To date, riociguat, macitentan, and subcutaneous treprostinil are the only drugs proven by randomized control trials to be capable of improving the exercise capacity (6-min walking distance) of CTEPH patients. In this review, we summarize the achievements and unresolved problems of PAH-targeted therapy for CTEPH over the last decade.
Similar content being viewed by others
References
Fedullo P, Kerr KM, Kim NH, Auger WR (2011) Chronic thromboembolic pulmonary hypertension. Am J Respir Crit Care Med 183:1605–1613. https://doi.org/10.1164/rccm.201011-1854CI
Ende-Verhaar YM, Cannegieter SC, Vonk Noordegraaf A, Delcroix M, Pruszczyk P, Mairuhu AT, Huisman MV, Klok FA (2017) Incidence of chronic thromboembolic pulmonary hypertension after acute pulmonary embolism: a contemporary view of the published literature. Eur Respir J 49:49. https://doi.org/10.1183/13993003.01792-2016
Hoeper MM, Mayer E, Simonneau G, Rubin LJ (2006) Chronic thromboembolic pulmonary hypertension. Circulation 113:2011–2020. https://doi.org/10.1161/circulationaha.105.602565
Lang IM, Madani M (2014) Update on chronic thromboembolic pulmonary hypertension. Circulation 130:508–518. https://doi.org/10.1161/circulationaha.114.009309
Galie N, Humbert M, Vachiery JL, Gibbs S, Lang I, Torbicki A, Simonneau G, Peacock A, Vonk Noordegraaf A, Beghetti M, Ghofrani A, Gomez Sanchez MA, Hansmann G, Klepetko W, Lancellotti P, Matucci M, McDonagh T, Pierard LA, Trindade PT, Zompatori M, Hoeper M (2016) 2015 ESC/ERS guidelines for the diagnosis and treatment of pulmonary hypertension: the joint task force for the diagnosis and treatment of pulmonary hypertension of the European Society of Cardiology (ESC) and the European Respiratory Society (ERS): endorsed by: Association for European Paediatric and Congenital Cardiology (AEPC), International Society for Heart and Lung Transplantation (ISHLT). Eur Heart J 37:67–119. https://doi.org/10.1093/eurheartj/ehv317
Simonneau G, D’Armini AM, Ghofrani HA, Grimminger F, Hoeper MM, Jansa P, Kim NH, Wang C, Wilkins MR, Fritsch A, Davie N, Colorado P, Mayer E (2015) Riociguat for the treatment of chronic thromboembolic pulmonary hypertension: a long-term extension study (CHEST-2). Eur Respir J 45:1293–1302. https://doi.org/10.1183/09031936.00087114
Pesavento R, Prandoni P (2018) Prevention and treatment of the chronic thromboembolic pulmonary hypertension. Thromb Res 164:150–156. https://doi.org/10.1016/j.thromres.2018.02.149
Tanabe N, Kawakami T, Satoh T, Matsubara H, Nakanishi N, Ogino H, Tamura Y, Tsujino I, Ogawa A, Sakao S, Nishizaki M, Ishida K, Ichimura Y, Yoshida M, Tatsumi K (2018) Balloon pulmonary angioplasty for chronic thromboembolic pulmonary hypertension: a systematic review. Respir Investig 56:332–341. https://doi.org/10.1016/j.resinv.2018.03.004
Tsuji A, Ogo T, Ueda J, Fukui S, Morita Y, Fukuda T, Nakanishi N, Ogawa H, Yasuda S (2017) Predictors of residual pulmonary hypertension after balloon pulmonary angioplasty in patients with chronic thromboembolic pulmonary hypertension. Int J Cardiol 226:118–120. https://doi.org/10.1016/j.ijcard.2016.09.132
Berger G, Azzam ZS, Hardak E, Tavor Y, Yigla M (2011) Idiopathic pulmonary arterial hypertension or chronic thromboembolic pulmonary hypertension: can we be certain? Isr Med Assoc J 13:106–110
Hoeper MM (2015) Pharmacological therapy for patients with chronic thromboembolic pulmonary hypertension. Eur Respir Rev 24:272–282. https://doi.org/10.1183/16000617.00001015
Matthews DT, Hemnes AR (2016) Current concepts in the pathogenesis of chronic thromboembolic pulmonary hypertension. Pulm Circ 6:145–154. https://doi.org/10.1086/686011
Satoh T, Satoh K, Yaoita N, Kikuchi N, Omura J, Kurosawa R, Numano K, Al-Mamun E, Siddique MA, Sunamura S, Nogi M, Suzuki K, Miyata S, Morser J, Shimokawa H (2017) Activated TAFI promotes the development of chronic thromboembolic pulmonary hypertension: a possible novel therapeutic target. Circ Res 120:1246–1262. https://doi.org/10.1161/circresaha.117.310640
Phan K, Jo HE, Xu J, Lau EM (2018) Medical therapy versus balloon angioplasty for CTEPH: a systematic review and meta-analysis. Heart Lung Circ 27:89–98. https://doi.org/10.1016/j.hlc.2017.01.016
Stasch JP, Pacher P, Evgenov OV (2011) Soluble guanylate cyclase as an emerging therapeutic target in cardiopulmonary disease. Circulation 123:2263–2273. https://doi.org/10.1161/circulationaha.110.981738
Grimminger F, Weimann G, Frey R, Voswinckel R, Thamm M, Bolkow D, Weissmann N, Muck W, Unger S, Wensing G, Schermuly RT, Ghofrani HA (2009) First acute haemodynamic study of soluble guanylate cyclase stimulator riociguat in pulmonary hypertension. Eur Respir J 33:785–792. https://doi.org/10.1183/09031936.00039808
Ghofrani HA, D’Armini AM, Grimminger F, Hoeper MM, Jansa P, Kim NH, Mayer E, Simonneau G, Wilkins MR, Fritsch A, Neuser D, Weimann G, Wang C (2013) Riociguat for the treatment of chronic thromboembolic pulmonary hypertension. N Engl J Med 369:319–329. https://doi.org/10.1056/NEJMoa1209657
McLaughlin VV, Gaine SP, Howard LS, Leuchte HH, Mathier MA, Mehta S, Palazzini M, Park MH, Tapson VF, Sitbon O (2013) Treatment goals of pulmonary hypertension. J Am Coll Cardiol 62:D73–D81. https://doi.org/10.1016/j.jacc.2013.10.034
Nickel N, Golpon H, Greer M, Knudsen L, Olsson K, Westerkamp V, Welte T, Hoeper MM (2012) The prognostic impact of follow-up assessments in patients with idiopathic pulmonary arterial hypertension. Eur Respir J 39:589–596. https://doi.org/10.1183/09031936.00092311
Gabler NB, French B, Strom BL, Palevsky HI, Taichman DB, Kawut SM, Halpern SD (2012) Validation of 6-minute walk distance as a surrogate end point in pulmonary arterial hypertension trials. Circulation 126:349–356. https://doi.org/10.1161/circulationaha.112.105890
Jamieson SW, Kapelanski DP, Sakakibara N, Manecke GR, Thistlethwaite PA, Kerr KM, Channick RN, Fedullo PF, Auger WR (2003) Pulmonary endarterectomy: experience and lessons learned in 1,500 cases. Ann Thorac Surg 76:1457–1462 discussion 1462-1454
D’Armini AM, Ghofrani HA, Kim NH, Mayer E, Morsolini M, Pulido-Zamudio T, Simonneau G, Wilkins MR, Curram J, Davie N, Hoeper MM (2015) Use of responder threshold criteria to evaluate the response to treatment in the phase III CHEST-1 study. J Heart Lung Transplant 34:348–355. https://doi.org/10.1016/j.healun.2015.02.003
Simonneau G, D’Armini AM, Ghofrani HA, Grimminger F, Jansa P, Kim NH, Mayer E, Pulido T, Wang C, Colorado P, Fritsch A, Meier C, Nikkho S, Hoeper MM (2016) Predictors of long-term outcomes in patients treated with riociguat for chronic thromboembolic pulmonary hypertension: data from the CHEST-2 open-label, randomised, long-term extension trial. Lancet Respir Med 4:372–380. https://doi.org/10.1016/s2213-2600(16)30022-4
Benza RL, Farber HW, Frost A, Grunig E, Hoeper MM, Busse D, Meier C, Nikkho S, Ghofrani HA (2018) REVEAL risk score in patients with chronic thromboembolic pulmonary hypertension receiving riociguat. J Heart Lung Transplant 37:836–843. https://doi.org/10.1016/j.healun.2018.02.015
Benza RL, Miller DP, Foreman AJ, Frost AE, Badesch DB, Benton WW, McGoon MD (2015) Prognostic implications of serial risk score assessments in patients with pulmonary arterial hypertension: a Registry to Evaluate Early and Long-Term Pulmonary Arterial Hypertension Disease Management (REVEAL) analysis. J Heart Lung Transplant 34:356–361. https://doi.org/10.1016/j.healun.2014.09.016
Benza RL, Miller DP, Gomberg-Maitland M, Frantz RP, Foreman AJ, Coffey CS, Frost A, Barst RJ, Badesch DB, Elliott CG, Liou TG, McGoon MD (2010) Predicting survival in pulmonary arterial hypertension: insights from the Registry to Evaluate Early and Long-Term Pulmonary Arterial Hypertension Disease Management (REVEAL). Circulation 122:164–172. https://doi.org/10.1161/circulationaha.109.898122
Benza RL, Miller DP, Barst RJ, Badesch DB, Frost AE, McGoon MD (2012) An evaluation of long-term survival from time of diagnosis in pulmonary arterial hypertension from the REVEAL registry. Chest 142:448–456. https://doi.org/10.1378/chest.11-1460
Halank M, Hoeper MM, Ghofrani HA, Meyer FJ, Stahler G, Behr J, Ewert R, Fletcher M, Colorado P, Nikkho S, Grimminger F (2017) Riociguat for pulmonary arterial hypertension and chronic thromboembolic pulmonary hypertension: results from a phase II long-term extension study. Respir Med 128:50–56. https://doi.org/10.1016/j.rmed.2017.05.008
McLaughlin VV, Jansa P, Nielsen-Kudsk JE, Halank M, Simonneau G, Grunig E, Ulrich S, Rosenkranz S, Gomez Sanchez MA, Pulido T, Pepke-Zaba J, Barbera JA, Hoeper MM, Vachiery JL, Lang I, Carvalho F, Meier C, Mueller K, Nikkho S, D’Armini AM (2017) Riociguat in patients with chronic thromboembolic pulmonary hypertension: results from an early access study. BMC Pulm Med 17:216. https://doi.org/10.1186/s12890-017-0563-7
Gall H, Vachiery JL, Tanabe N, Halank M, Orozco-Levi M, Mielniczuk L, Chang M, Vogtlander K, Grunig E (2018) Real-world switching to riociguat: management and practicalities in patients with PAH and CTEPH. Lung 196:305–312. https://doi.org/10.1007/s00408-018-0100-3
Hill NS, Rahaghi FF, Sood N, Frey R, Ghofrani HA (2017) Individual dose adjustment of riociguat in patients with pulmonary arterial hypertension and chronic thromboembolic pulmonary hypertension. Respir Med 129:124–129. https://doi.org/10.1016/j.rmed.2017.05.005
Frey R, Becker C, Unger S, Schmidt A, Wensing G, Muck W (2016) Assessment of the effects of hepatic impairment and smoking on the pharmacokinetics of a single oral dose of the soluble guanylate cyclase stimulator riociguat (BAY 63-2521). Pulm Circ 6:S5–S14. https://doi.org/10.1086/685015
Saleh S, Becker C, Frey R, Muck W (2016) Population pharmacokinetics and the pharmacokinetic/pharmacodynamic relationship of riociguat in patients with pulmonary arterial hypertension or chronic thromboembolic pulmonary hypertension. Pulm Circ 6:S86–S96. https://doi.org/10.1086/685404
Frey R, Becker C, Unger S, Schmidt A, Wensing G, Muck W (2016) Assessment of the effects of renal impairment and smoking on the pharmacokinetics of a single oral dose of the soluble guanylate cyclase stimulator riociguat (BAY 63-2521). Pulm Circ 6:S15–S26. https://doi.org/10.1086/685017
Delcroix M, Lang I, Pepke-Zaba J, Jansa P, D’Armini AM, Snijder R, Bresser P, Torbicki A, Mellemkjaer S, Lewczuk J, Simkova I, Barbera JA, de Perrot M, Hoeper MM, Gaine S, Speich R, Gomez-Sanchez MA, Kovacs G, Jais X, Ambroz D, Treacy C, Morsolini M, Jenkins D, Lindner J, Dartevelle P, Mayer E, Simonneau G (2016) Long-term outcome of patients with chronic thromboembolic pulmonary hypertension: results from an international prospective registry. Circulation 133:859–871. https://doi.org/10.1161/circulationaha.115.016522
Pepke-Zaba J, Delcroix M, Lang I, Mayer E, Jansa P, Ambroz D, Treacy C, D’Armini AM, Morsolini M, Snijder R, Bresser P, Torbicki A, Kristensen B, Lewczuk J, Simkova I, Barbera JA, de Perrot M, Hoeper MM, Gaine S, Speich R, Gomez-Sanchez MA, Kovacs G, Hamid AM, Jais X, Simonneau G (2011) Chronic thromboembolic pulmonary hypertension (CTEPH): results from an international prospective registry. Circulation 124:1973–1981. https://doi.org/10.1161/circulationaha.110.015008
Marra AM, Egenlauf B, Ehlken N, Fischer C, Eichstaedt C, Nagel C, Bossone E, Cittadini A, Halank M, Gall H, Olsson KM, Lange TJ, Grunig E (2015) Change of right heart size and function by long-term therapy with riociguat in patients with pulmonary arterial hypertension and chronic thromboembolic pulmonary hypertension. Int J Cardiol 195:19–26. https://doi.org/10.1016/j.ijcard.2015.05.105
Ahmadi A, Thornhill RE, Pena E, Renaud JM, Promislow S, Chandy G, Davies RA, Stewart DJ, Contreras-Dominguez V, Dunne R, Doyle-Cox C, Beanlands RS, deKemp RA, Mielniczuk LM (2018) Effects of riociguat on right ventricular remodelling in chronic thromboembolic pulmonary hypertension patients: a prospective study. Can J Cardiol 34:1137–1144. https://doi.org/10.1016/j.cjca.2018.06.007
Weir NA, Conrey A, Lewis D, Mehari A (2018) Riociguat use in sickle cell related chronic thromboembolic pulmonary hypertension: a case series. Pulm Circ 8:2045894018791802. https://doi.org/10.1177/2045894018791802
Ahn HS, Foster M, Cable M, Pitts BJ, Sybertz EJ (1991) Ca/CaM-stimulated and cGMP-specific phosphodiesterases in vascular and non-vascular tissues. Adv Exp Med Biol 308:191–197
Suntharalingam J, Hughes RJ, Goldsmith K, Doughty N, George P, Toshner M, Sheares KK, Pepke-Zaba J (2007) Acute haemodynamic responses to inhaled nitric oxide and intravenous sildenafil in distal chronic thromboembolic pulmonary hypertension (CTEPH). Vasc Pharmacol 46:449–455. https://doi.org/10.1016/j.vph.2007.01.008
Reichenberger F, Voswinckel R, Enke B, Rutsch M, El Fechtali E, Schmehl T, Olschewski H, Schermuly R, Weissmann N, Ghofrani HA, Grimminger F, Mayer E, Seeger W (2007) Long-term treatment with sildenafil in chronic thromboembolic pulmonary hypertension. Eur Respir J 30:922–927. https://doi.org/10.1183/09031936.00039007
Suntharalingam J, Treacy CM, Doughty NJ, Goldsmith K, Soon E, Toshner MR, Sheares KK, Hughes R, Morrell NW, Pepke-Zaba J (2008) Long-term use of sildenafil in inoperable chronic thromboembolic pulmonary hypertension. Chest 134:229–236. https://doi.org/10.1378/chest.07-2681
Toshner MR, Gopalan D, Suntharalingam J, Treacy C, Soon E, Sheares KK, Morrell NW, Screaton N, Pepke-Zaba J (2010) Pulmonary arterial size and response to sildenafil in chronic thromboembolic pulmonary hypertension. J Heart Lung Transplant 29:610–615. https://doi.org/10.1016/j.healun.2009.12.014
Sekine A, Tanabe N, Sugiura T, Shigeta A, Jujo T, Nishimura R, Sakao S, Kasahara Y, Tatsumi K (2014) Polymorphism of the G protein beta3 subunit gene influences the efficacy of sildenafil in patients with pulmonary hypertension. Intern Med 53:291–297
Nishimura R, Tanabe N, Sekine A, Kasai H, Suda R, Kato F, Jujo T, Sugiura T, Shigeta A, Sakao S, Tatsumi K (2016) Synergistic effects of ACE insertion/deletion and GNB3 C825T polymorphisms on the efficacy of PDE-5 inhibitor in patients with pulmonary hypertension. Respiration 91:132–140. https://doi.org/10.1159/000443772
Claessen G, La Gerche A, Wielandts JY, Bogaert J, Van Cleemput J, Wuyts W, Claus P, Delcroix M, Heidbuchel H (2015) Exercise pathophysiology and sildenafil effects in chronic thromboembolic pulmonary hypertension. Heart 101:637–644. https://doi.org/10.1136/heartjnl-2014-306851
Yamamura A, Fujitomi E, Ohara N, Tsukamoto K, Sato M, Yamamura H (2017) Tadalafil induces antiproliferation, apoptosis, and phosphodiesterase type 5 downregulation in idiopathic pulmonary arterial hypertension in vitro. Eur J Pharmacol 810:44–50. https://doi.org/10.1016/j.ejphar.2017.06.010
Southwood M, MacKenzie Ross RV, Kuc RE, Hagan G, Sheares KK, Jenkins DP, Goddard M, Davenport AP, Pepke-Zaba J (2016) Endothelin ETA receptors predominate in chronic thromboembolic pulmonary hypertension. Life Sci 159:104–110. https://doi.org/10.1016/j.lfs.2016.02.036
Reesink HJ, Meijer RC, Lutter R, Boomsma F, Jansen HM, Kloek JJ, Bresser P (2006) Hemodynamic and clinical correlates of endothelin-1 in chronic thromboembolic pulmonary hypertension. Circ J 70:1058–1063
Bauer M, Wilkens H, Langer F, Schneider SO, Lausberg H, Schafers HJ (2002) Selective upregulation of endothelin B receptor gene expression in severe pulmonary hypertension. Circulation 105:1034–1036
Jais X, D’Armini AM, Jansa P, Torbicki A, Delcroix M, Ghofrani HA, Hoeper MM, Lang IM, Mayer E, Pepke-Zaba J, Perchenet L, Morganti A, Simonneau G, Rubin LJ (2008) Bosentan for treatment of inoperable chronic thromboembolic pulmonary hypertension: BENEFiT (Bosentan Effects in iNopErable Forms of chronIc Thromboembolic pulmonary hypertension), a randomized, placebo-controlled trial. J Am Coll Cardiol 52:2127–2134. https://doi.org/10.1016/j.jacc.2008.08.059
Nishikawa-Takahashi M, Ueno S, Kario K (2014) Long-term advanced therapy with bosentan improves symptoms and prevents deterioration of inoperable chronic thromboembolic pulmonary hypertension. Life Sci 118:410–413. https://doi.org/10.1016/j.lfs.2014.03.024
Post MC, Plokker HW, Kelder JC, Snijder RJ (2009) Long-term efficacy of bosentan in inoperable chronic thromboembolic pulmonary hypertension. Neth Hear J 17:329–333
Ulrich S, Speich R, Domenighetti G, Geiser T, Aubert JD, Rochat T, Huber L, Treder U, Fischler M (2007) Bosentan therapy for chronic thromboembolic pulmonary hypertension. A national open label study assessing the effect of bosentan on haemodynamics, exercise capacity, quality of life, safety and tolerability in patients with chronic thromboembolic pulmonary hypertension (BOCTEPH-study). Swiss Med Wkly 137:573–580
Vassallo FG, Kodric M, Scarduelli C, Harari S, Potena A, Scarda A, Piattella M, Cassandro R, Confalonieri M (2009) Bosentan for patients with chronic thromboembolic pulmonary hypertension. Eur J Intern Med 20:24–29. https://doi.org/10.1016/j.ejim.2008.03.008
Becattini C, Manina G, Busti C, Gennarini S, Agnelli G (2010) Bosentan for chronic thromboembolic pulmonary hypertension: findings from a systematic review and meta-analysis. Thromb Res 126:e51–e56. https://doi.org/10.1016/j.thromres.2010.01.007
Chen X, Zhai Z, Huang K, Xie W, Wan J, Wang C (2018) Bosentan therapy for pulmonary arterial hypertension and chronic thromboembolic pulmonary hypertension: a systemic review and meta-analysis. Clin Respir J 12:2065–2074. https://doi.org/10.1111/crj.12774
Hirashiki A, Adachi S, Nakano Y, Kamimura Y, Shimokata S, Takeshita K, Murohara T, Kondo T (2016) Effects of bosentan on peripheral endothelial function in patients with pulmonary arterial hypertension or chronic thromboembolic pulmonary hypertension. Pulm Circ 6:168–173. https://doi.org/10.1086/685715
Gatfield J, Mueller Grandjean C, Sasse T, Clozel M, Nayler O (2012) Slow receptor dissociation kinetics differentiate macitentan from other endothelin receptor antagonists in pulmonary arterial smooth muscle cells. PLoS One 7:e47662. https://doi.org/10.1371/journal.pone.0047662
Ghofrani HA, Simonneau G, D’Armini AM, Fedullo P, Howard LS, Jais X, Jenkins DP, Jing ZC, Madani MM, Martin N, Mayer E, Papadakis K, Richard D, Kim NH (2017) Macitentan for the treatment of inoperable chronic thromboembolic pulmonary hypertension (MERIT-1): results from the multicentre, phase 2, randomised, double-blind, placebo-controlled study. Lancet Respir Med 5:785–794. https://doi.org/10.1016/s2213-2600(17)30305-3
Clapp LH, Gurung R (2015) The mechanistic basis of prostacyclin and its stable analogues in pulmonary arterial hypertension: role of membrane versus nuclear receptors. Prostaglandins Other Lipid Mediat 120:56–71. https://doi.org/10.1016/j.prostaglandins.2015.04.007
Scelsi L, Ghio S, Campana C, D’Armini AM, Serio A, Klersy C, Piovella F, Vigano M, Tavazzi L (2004) Epoprostenol in chronic thromboembolic pulmonary hypertension with distal lesions. Ital Heart J 5:618–623
Cabrol S, Souza R, Jais X, Fadel E, Ali RH, Humbert M, Dartevelle P, Simonneau G, Sitbon O (2007) Intravenous epoprostenol in inoperable chronic thromboembolic pulmonary hypertension. J Heart Lung Transplant 26:357–362. https://doi.org/10.1016/j.healun.2006.12.014
Ikari J, Tanabe N, Tatsuno I, Yamanaka M, Sakao S, Tada Y, Kurosu K, Kasahara Y, Takiguchi Y, Tatsumi K (2011) ACTH deficiency and PGI(2) therapy in chronic thromboembolic pulmonary hypertension. Int J Cardiol 146:449–450. https://doi.org/10.1016/j.ijcard.2010.10.115
Olschewski H, Simonneau G, Galie N, Higenbottam T, Naeije R, Rubin LJ, Nikkho S, Speich R, Hoeper MM, Behr J, Winkler J, Sitbon O, Popov W, Ghofrani HA, Manes A, Kiely DG, Ewert R, Meyer A, Corris PA, Delcroix M, Gomez-Sanchez M, Siedentop H, Seeger W (2002) Inhaled iloprost for severe pulmonary hypertension. N Engl J Med 347:322–329. https://doi.org/10.1056/NEJMoa020204
Krug S, Hammerschmidt S, Pankau H, Wirtz H, Seyfarth HJ (2008) Acute improved hemodynamics following inhaled iloprost in chronic thromboembolic pulmonary hypertension. Respiration 76:154–159. https://doi.org/10.1159/000107977
Ulrich S, Fischler M, Speich R, Popov V, Maggiorini M (2006) Chronic thromboembolic and pulmonary arterial hypertension share acute vasoreactivity properties. Chest 130:841–846. https://doi.org/10.1378/chest.130.3.841
Reichenberger F, Mainwood A, Doughty N, Fineberg A, Morrell NW, Pepke-Zaba J (2007) Effects of nebulised iloprost on pulmonary function and gas exchange in severe pulmonary hypertension. Respir Med 101:217–222. https://doi.org/10.1016/j.rmed.2006.05.019
Lang I, Gomez-Sanchez M, Kneussl M, Naeije R, Escribano P, Skoro-Sajer N, Vachiery JL (2006) Efficacy of long-term subcutaneous treprostinil sodium therapy in pulmonary hypertension. Chest 129:1636–1643. https://doi.org/10.1378/chest.129.6.1636
Skoro-Sajer N, Bonderman D, Wiesbauer F, Harja E, Jakowitsch J, Klepetko W, Kneussl MP, Lang IM (2007) Treprostinil for severe inoperable chronic thromboembolic pulmonary hypertension. J Thromb Haemost 5:483–489. https://doi.org/10.1111/j.1538-7836.2007.02394.x
Sadushi-Kolici R, Jansa P, Kopec G, Torbicki A, Skoro-Sajer N, Campean IA, Halank M, Simkova I, Karlocai K, Steringer-Mascherbauer R, Samarzija M, Salobir B, Klepetko W, Lindner J, Lang IM (2019) Subcutaneous treprostinil for the treatment of severe non-operable chronic thromboembolic pulmonary hypertension (CTREPH): a double-blind, phase 3, randomised controlled trial. Lancet Respir Med 7:239–248. https://doi.org/10.1016/s2213-2600(18)30367-9
Ono F, Nagaya N, Okumura H, Shimizu Y, Kyotani S, Nakanishi N, Miyatake K (2003) Effect of orally active prostacyclin analogue on survival in patients with chronic thromboembolic pulmonary hypertension without major vessel obstruction. Chest 123:1583–1588
Nagaya N, Shimizu Y, Satoh T, Oya H, Uematsu M, Kyotani S, Sakamaki F, Sato N, Nakanishi N, Miyatake K (2002) Oral beraprost sodium improves exercise capacity and ventilatory efficiency in patients with primary or thromboembolic pulmonary hypertension. Heart 87:340–345
Vizza CD, Badagliacca R, Sciomer S, Poscia R, Battagliese A, Schina M, Agati L, Fedele F (2006) Mid-term efficacy of beraprost, an oral prostacyclin analog, in the treatment of distal CTEPH: a case control study. Cardiology 106:168–173. https://doi.org/10.1159/000092920
Holmboe S, Andersen A, Jensen RV, Kimose HH, Ilkjaer LB, Shen L, Clapp LH, Nielsen-Kudsk JE (2017) Prostacyclins have no direct inotropic effect on isolated atrial strips from the normal and pressure-overloaded human right heart. Pulm Circ 7:339–347. https://doi.org/10.1177/2045893217691532
Sitbon O, Channick R, Chin KM, Frey A, Gaine S, Galie N, Ghofrani HA, Hoeper MM, Lang IM, Preiss R, Rubin LJ, Di Scala L, Tapson V, Adzerikho I, Liu J, Moiseeva O, Zeng X, Simonneau G, McLaughlin VV (2015) Selexipag for the treatment of pulmonary arterial hypertension. N Engl J Med 373:2522–2533. https://doi.org/10.1056/NEJMoa1503184
Thurber KM, Williams BM, Bates RE, Frantz RP (2017) Transition of intravenous treprostinil to oral therapy in a patient with functional class IV chronic thromboembolic pulmonary hypertension. Pharmacotherapy 37:e76–e81. https://doi.org/10.1002/phar.1951
Gall H, Preston IR, Hinzmann B, Heinz S, Jenkins D, Kim NH, Lang I (2016) An international physician survey of chronic thromboembolic pulmonary hypertension management. Pulm Circ 6:472–482. https://doi.org/10.1086/688084
Ghofrani HA, Wiedemann R, Rose F, Olschewski H, Schermuly RT, Weissmann N, Seeger W, Grimminger F (2002) Combination therapy with oral sildenafil and inhaled iloprost for severe pulmonary hypertension. Ann Intern Med 136:515–522
Voswinckel R, Reichenberger F, Enke B, Kreckel A, Krick S, Gall H, Schermuly RT, Grimminger F, Rubin LJ, Olschewski H, Seeger W, Ghofrani HA (2008) Acute effects of the combination of sildenafil and inhaled treprostinil on haemodynamics and gas exchange in pulmonary hypertension. Pulm Pharmacol Ther 21:824–832. https://doi.org/10.1016/j.pupt.2008.07.003
Horng M, Mohammad I, Smith ZR, Awdish RL, Cajigas HR (2016) Inhaled iloprost for chronic thromboembolic pulmonary hypertension (CTEPH) during pregnancy: a case report. Pharmacotherapy 36(9):e142–e147. https://doi.org/10.1002/phar.1793
Swisher JW, Elliott D (2017) Combination therapy with riociquat and inhaled treprostinil in inoperable and progressive chronic thromboembolic pulmonary hypertension. Respir Med Case Rep 20:45–47. https://doi.org/10.1016/j.rmcr.2016.11.012
Tromeur C, Jais X, Mercier O, Couturaud F, Montani D, Savale L, Jevnikar M, Weatherald J, Sitbon O, Parent F, Fabre D, Mussot S, Dartevelle P, Humbert M, Simonneau G, Fadel E (2018) Factors predicting outcome after pulmonary endarterectomy. PLoS One 13:e0198198. https://doi.org/10.1371/journal.pone.0198198
Nagaya N, Sasaki N, Ando M, Ogino H, Sakamaki F, Kyotani S, Nakanishi N (2003) Prostacyclin therapy before pulmonary thromboendarterectomy in patients with chronic thromboembolic pulmonary hypertension. Chest 123:338–343
Reesink HJ, Surie S, Kloek JJ, Tan HL, Tepaske R, Fedullo PF, Bresser P (2010) Bosentan as a bridge to pulmonary endarterectomy for chronic thromboembolic pulmonary hypertension. J Thorac Cardiovasc Surg 139:85–91. https://doi.org/10.1016/j.jtcvs.2009.03.053
Surie S, Reesink HJ, Marcus JT, van der Plas MN, Kloek JJ, Vonk-Noordegraaf A, Bresser P (2013) Bosentan treatment is associated with improvement of right ventricular function and remodeling in chronic thromboembolic pulmonary hypertension. Clin Cardiol 36:698–703. https://doi.org/10.1002/clc.22197
Kramm T, Eberle B, Krummenauer F, Guth S, Oelert H, Mayer E (2003) Inhaled iloprost in patients with chronic thromboembolic pulmonary hypertension: effects before and after pulmonary thromboendarterectomy. Ann Thorac Surg 76:711–718
Jensen KW, Kerr KM, Fedullo PF, Kim NH, Test VJ, Ben-Yehuda O, Auger WR (2009) Pulmonary hypertensive medical therapy in chronic thromboembolic pulmonary hypertension before pulmonary thromboendarterectomy. Circulation 120:1248–1254. https://doi.org/10.1161/circulationaha.109.865881
Charalampopoulos A, Gibbs JS, Davies RJ, Gin-Sing W, Murphy K, Sheares KK, Pepke-Zaba J, Jenkins DP, Howard LS (2016) Exercise physiological responses to drug treatments in chronic thromboembolic pulmonary hypertension. J Appl Physiol 121:623–628. https://doi.org/10.1152/japplphysiol.00087.2016
Inami T, Kataoka M, Shimura N, Ishiguro H, Yanagisawa R, Taguchi H, Fukuda K, Yoshino H, Satoh T (2013) Pulmonary edema predictive scoring index (PEPSI), a new index to predict risk of reperfusion pulmonary edema and improvement of hemodynamics in percutaneous transluminal pulmonary angioplasty. JACC Cardiovasc Interv 6:725–736. https://doi.org/10.1016/j.jcin.2013.03.009
Inami T, Kataoka M, Shimura N, Ishiguro H, Yanagisawa R, Fukuda K, Yoshino H, Satoh T (2014) Pressure-wire-guided percutaneous transluminal pulmonary angioplasty: a breakthrough in catheter-interventional therapy for chronic thromboembolic pulmonary hypertension. JACC Cardiovasc Interv 7:1297–1306. https://doi.org/10.1016/j.jcin.2014.06.010
Feinstein JA, Goldhaber SZ, Lock JE, Ferndandes SM, Landzberg MJ (2001) Balloon pulmonary angioplasty for treatment of chronic thromboembolic pulmonary hypertension. Circulation 103:10–13
Mizoguchi H, Ogawa A, Munemasa M, Mikouchi H, Ito H, Matsubara H (2012) Refined balloon pulmonary angioplasty for inoperable patients with chronic thromboembolic pulmonary hypertension. Circ Cardiovasc Interv 5:748–755. https://doi.org/10.1161/circinterventions.112.971077
Sugimura K, Fukumoto Y, Satoh K, Nochioka K, Miura Y, Aoki T, Tatebe S, Miyamichi-Yamamoto S, Shimokawa H (2012) Percutaneous transluminal pulmonary angioplasty markedly improves pulmonary hemodynamics and long-term prognosis in patients with chronic thromboembolic pulmonary hypertension. Circ J 76:485–488
Galie N, Olschewski H, Oudiz RJ, Torres F, Frost A, Ghofrani HA, Badesch DB, McGoon MD, McLaughlin VV, Roecker EB, Gerber MJ, Dufton C, Wiens BL, Rubin LJ (2008) Ambrisentan for the treatment of pulmonary arterial hypertension: results of the ambrisentan in pulmonary arterial hypertension, randomized, double-blind, placebo-controlled, multicenter, efficacy (ARIES) study 1 and 2. Circulation 117:3010–3019. https://doi.org/10.1161/circulationaha.107.742510
Divers C, Platt D, Wang E, Lin J, Lingohr-Smith M, Mathai SC (2017) A review of clinical trial endpoints of patients with pulmonary arterial hypertension and chronic thromboembolic pulmonary hypertension and how they relate to patient outcomes in the United States. J Manag Care Spec Pharm 23:92–104. https://doi.org/10.18553/jmcp.2017.23.1.92
Funding
This review article was supported by the National Natural Science Foundation of China (81370326, 81641005), Beijing Municipal Science and Technology Project (Z181100001718200), and National Precision Medical Research Program of China (2016YFC0905602).
Author information
Authors and Affiliations
Corresponding author
Ethics declarations
Conflict of interest
The authors declare that they have no conflicts of interest.
Additional information
Publisher’s note
Springer Nature remains neutral with regard to jurisdictional claims in published maps and institutional affiliations.
Rights and permissions
About this article
Cite this article
Zhang, Y., Yu, X., Jin, Q. et al. Advances in targeted therapy for chronic thromboembolic pulmonary hypertension. Heart Fail Rev 24, 949–965 (2019). https://doi.org/10.1007/s10741-019-09798-x
Published:
Issue Date:
DOI: https://doi.org/10.1007/s10741-019-09798-x